Eris Lifesciences Allots 24,396 Equity Shares Under ESOP-2021 Scheme, Paid-Up Capital Rises to ₹13,85,67,256

1 min read     Updated on 11 May 2026, 11:54 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Eris Lifesciences allotted 24,396 equity shares on May 11, 2026 under its ESOP-2021 Scheme, covering grant years 2022, 2023, and 2024 at issue prices of Rs. 557.24, Rs. 510.32, and Rs. 728.16 per share respectively. The allotment increased the company's paid-up share capital from ₹13,85,42,887 to ₹13,85,67,256, with each equity share carrying a face value of ₹1. The development was disclosed to BSE Limited and the National Stock Exchange of India Limited by Company Secretary Milind Talegaonkar.

powered bylight_fuzz_icon
40026242

*this image is generated using AI for illustrative purposes only.

Eris Lifesciences announced the allotment of 24,396 equity shares on May 11, 2026, pursuant to the exercise of stock options under its ESOP-2021 Scheme. The allotment was formally communicated to both BSE Limited and the National Stock Exchange of India Limited by Milind Talegaonkar, Company Secretary and Compliance Officer.

ESOP-2021 Scheme Allotment Details

The allotment under the ESOP-2021 Scheme spans three grant years, with varying issue prices per share for each year. The following table provides a breakdown of the shares allotted and the corresponding issue prices:

Parameter: Grant Year 2022 Grant Year 2023 Grant Year 2024
ESOP Scheme: ESOP-2021 Scheme ESOP-2021 Scheme ESOP-2021 Scheme
Equity Shares Allotted: 6,415 8,281 9,673
Issue Price Per Share: Rs. 557.24 Rs. 510.32 Rs. 728.16

The total of 24,396 equity shares allotted on May 11, 2026 reflects the cumulative exercise of options across these three grant years under the ESOP-2021 Scheme.

Impact on Paid-Up Share Capital

Following the allotment, the paid-up share capital of Eris Lifesciences has been revised upward. Each equity share carries a face value of ₹1. The table below summarises the change in paid-up share capital:

Metric: Details
Pre-Allotment Paid-Up Capital: ₹13,85,42,887 (13,85,42,887 equity shares of ₹1 each)
Post-Allotment Paid-Up Capital: ₹13,85,67,256 (13,85,67,256 equity shares of ₹1 each)
Shares Allotted: 24,396 equity shares
Allotment Date: May 11, 2026

The disclosure was made in compliance with applicable listing obligations, and the information has been submitted for record with both stock exchanges. The communication was signed by Milind Talegaonkar, Company Secretary and Compliance Officer, bearing ICSI Membership No. A26493, with a digital signature dated May 11, 2026.

Historical Stock Returns for Eris Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.99%-1.08%-2.37%-10.61%-6.07%+102.45%

How might the continued dilution from ESOP-2021 Scheme exercises impact Eris Lifesciences' earnings per share trajectory over the next few quarters?

Given the varying issue prices across grant years (Rs. 557–728), what does the pattern of employee option exercises suggest about insider confidence in Eris Lifesciences' future stock performance?

Are there additional tranches of unexercised options under the ESOP-2021 Scheme that could further dilute the paid-up share capital, and what is the potential total dilution exposure?

Eris Lifesciences Limited Announces Postal Ballot for Appointment of Independent Director

2 min read     Updated on 24 Apr 2026, 04:38 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Eris Lifesciences Limited has issued a postal ballot notice seeking member approval for the appointment of Mr. Vineet Varma as an Independent Director. The remote e-voting period is scheduled from April 24, 2026, to May 23, 2026, with the cut-off date for eligibility set as April 17, 2026. The company has engaged MUFG Intime India Private Limited as the Registrar and Share Transfer Agent to facilitate the e-voting process. Mr. Ravi Kapoor has been appointed as the Scrutinizer to ensure fair conduct of the postal ballot. The results will be announced on or before May 25, 2026, and will be displayed on the company's website and communicated to the stock exchanges.

powered bylight_fuzz_icon
38531310

*this image is generated using AI for illustrative purposes only.

Eris Lifesciences Limited has issued a postal ballot notice seeking member approval for the appointment of Mr. Vineet Varma as an Independent Director of the company. The notice, dated April 23, 2026, has been dispatched in electronic form to all members whose names appear in the Register of Members or Register of Beneficial Owners maintained by NSDL and CDSL as on the cut-off date of April 17, 2026.

The proposed resolution seeks approval for appointing Mr. Vineet Varma (DIN: 11600100) as a Non-Executive and Independent Director for a term of five consecutive years commencing from March 14, 2026, to March 13, 2031. The appointment is subject to the approval of members and follows his initial appointment as an Additional Director. Mr. Varma brings over 25 years of professional experience, having worked with international banks including First Abu Dhabi Bank and ABN Amro Bank across various financial domains.

E-Voting Schedule and Process

The company has facilitated remote e-voting in compliance with the SEBI Listing Regulations and relevant circulars issued by the Ministry of Corporate Affairs and SEBI. The e-voting period is scheduled as follows:

| --- | --- | | Commencement of remote e-voting period | 9.00 A.M. IST on Friday, April 24, 2026 | | Conclusion of remote e-voting period | 5.00 P.M. IST on Saturday, May 23, 2026 | | Cut-off date for eligibility to vote | Friday, April 17, 2026 |

Members can cast their votes electronically through multiple methods including NSDL and CDSL depository facilities, depository participant websites, or directly through the InstaVote platform. The company has engaged MUFG Intime India Private Limited (formerly Link Intime India Private Limited) as the Registrar and Share Transfer Agent to facilitate the e-voting process.

Scrutinizer and Results Declaration

Mr. Ravi Kapoor, a Practicing Company Secretary (FCS No. 2587; COP No 2407) and proprietor of M/s. Ravi Kapoor & Associates, Ahmedabad, has been appointed as the Scrutinizer to conduct the postal ballot process in a fair and transparent manner. The Scrutinizer will submit the results to the Chairman after completion of the scrutiny of e-votes.

The results of the postal ballot along with the Scrutinizer's Report will be displayed on the company's website at https://eris.co.in/ , on the MUFG website at https://instavote.linkintime.co.in/ , and at the Registered Office of the Company on or before Monday, May 25, 2026. The results will be simultaneously communicated to the National Stock Exchange of India Limited and BSE Limited, where the equity shares of the company are listed.

Director Profile and Disclosures

Mr. Vineet Varma has submitted all statutory disclosures and declarations necessary for directorship, including written consent to act as director, confirmation of non-disqualification under Section 164(2) of the Companies Act, 2013, and declaration of meeting independence criteria under Section 149(6) of the Act and SEBI Listing Regulations, 2015. He is an alumnus of the London Business School and Shriram College of Commerce, New Delhi, and has served on the Client Advisory Board of Citibank and Bank of America Merrill Lynch.

The company has received the recommendation of the Nomination and Remuneration Committee for his candidature. The appointment, if approved by members, will be effective from March 14, 2026, and Mr. Varma will not be liable to retire by rotation. He will be entitled to receive sitting fees for attending meetings of the Board and its Committees as determined by the Board from time to time in accordance with applicable laws and company policies.

Historical Stock Returns for Eris Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.99%-1.08%-2.37%-10.61%-6.07%+102.45%

What strategic initiatives or business expansion plans might Eris Lifesciences be considering that require Mr. Varma's extensive banking and financial expertise?

How could Mr. Varma's international banking experience with trade finance and supply chain financing impact Eris Lifesciences' global market penetration strategy?

Will this board appointment signal potential changes in Eris Lifesciences' capital structure or financing approach given the new director's treasury and corporate banking background?

More News on Eris Lifesciences

1 Year Returns:-6.07%